SCHEMBL664890

SCHEMBL664890

Cc1ccc(S(=O)(=O)n2cc(-c3cc(-c4ccccc4)no3)c3nc(-c4ccc(S(=O)(=O)C(C)C)cc4)cnc32)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATR Q13535 17/20 0.56
ATM Q13315 12/20 0.56
GSK3B P49841 4/20 0.56
PRKDC P78527 7/20 0.47
JAK2 O60674 1/20 0.46
ABL1 P00519 1/20 0.46
KIT P10721 1/20 0.46
SERPINA2 P20848 1/20 0.46
PIK3R1 P27986 1/20 0.46
FLT4 P35916 1/20 0.46
FLT3 P36888 1/20 0.46
PIK3CA P42336 1/20 0.46
MTOR P42345 1/20 0.46
SYK P43405 1/20 0.46
GSK3A P49840 1/20 0.46
MAP3K9 P80192 1/20 0.46
KCNH2 Q12809 1/20 0.46
MERTK Q12866 1/20 0.46
DYRK2 Q92630 1/20 0.46
NPC1 O15118 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10173418 0.89 L3MBTL1 (0.46) ATRATMGSK3BPRKDCMAPT
SCHEMBL668030 0.83 L3MBTL1 (0.40) ATRATMGSK3BPRKDCPTGS2
SCHEMBL14375195 0.80 ATR (0.41) ATRATMGSK3BPRKDC
SCHEMBL667758 0.80 ATR (0.39) ATRATMGSK3BPRKDCJAK2
SCHEMBL667102 0.79 ATR (0.41) ATRATMGSK3BPRKDC
SCHEMBL10173334 0.79 ATR (0.39) ATRATMGSK3BPRKDC
SCHEMBL665615 0.78 ATR (0.40) ATRATMGSK3BPRKDC
SCHEMBL667591 0.77 ATR (0.38) ATRATMGSK3BPRKDCJAK2
SCHEMBL666906 0.77 ATR (0.64) ATRATMGSK3BPRKDCJAK2
SCHEMBL14332008 0.76 ATR (0.47) ATRATMGSK3BPRKDCNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160009723-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-01-14 US disclosed
US-20160009723-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-01-14 US disclosed
US-20160009723-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-01-14 US disclosed
US-20140288347-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-25 US disclosed
US-20140288347-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-25 US disclosed
US-20140288347-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-25 US disclosed
US-8623869-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-07 US disclosed
US-8623869-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-07 US disclosed
US-8623869-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-07 US disclosed
EP-2585468-A1 PYRROLO- PYRAZINE DERIVATIVES USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2013-05-01 EP disclosed
US-20120046295-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-23 US disclosed
US-20120046295-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-23 US disclosed
US-20120046295-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-23 US disclosed
WO-2011163527-A1 PYRROLO- PYRAZINE DERIVATIVES USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-12-29 WO disclosed
WO-2011163527-A1 PYRROLO- PYRAZINE DERIVATIVES USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140288347-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, MAP3K5 ATR 1/4885ATM 50/4885GSK3B 256/4885
US-20120046295-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, MAP3K5 ATR 1/4885ATM 50/4885GSK3B 256/4885
US-20160009723-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, MAP3K5 ATR 1/4885ATM 50/4885GSK3B 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.